After harsh light, a cheaper version of EpiPen from Mylan
Mylan is releasing a generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew scorn from parents nationwide and spawned Congressional inquiries.
The potential cost savings will depend in part on a patient’s insurance coverage and qualifications for discount and assistance programs that the drugmaker also provides.
For Mylan, the benefit from its long-promised generic is more certain: It is expected to generate millions of dollars in revenue while also protecting the drugmaker’s market share against competition.
Mylan NV said Friday that it will charge $300 for the generic version of its life-saving injections, which come in a two pack. The generic version will begin to reach retail pharmacies next week.